Market Overview

UPDATE: Deutsche Bank Raises PT on Vertex Pharmaceuticals on 661 Data


In a report published Friday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX), and raised the price target from $75.00 to $100.00.

In the report, Karnauskas noted, “661 data released today beat our positive expectations. We now model c100% success in F508del homozygous (prev. 75%) and 100% success in other Kalydeco mutations (prev. 50%), and increase market size oppy for other mutations. We also see oppy's for upside leading to VRTX FVs of $100-$150/sh. We are increasing our TP to $100 for the reasons above and reiterate our Buy rating.”

Vertex Pharmaceuticals closed on Thursday at $52.87.

Latest Ratings for VRTX

Nov 2020BernsteinInitiates Coverage OnOutperform
Oct 2020Credit SuisseMaintainsOutperform
Oct 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at